Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by DryBoneson Mar 15, 2018 3:39pm
200 Views
Post# 27722792

RE:With all the good news sp keeps going

RE:With all the good news sp keeps goingIt looks like the market place is evenly divided on the prospects for PLI and its medical and scientific innovations.

What do we have to go on to decide for ourselves:  yeah, or nay.  We can listen to the usually false prophets such as CIBC and other institutional advisors,  we can listen to our deranged pumpers, or we can listen to our gut instincts.  

Of little help is the fact that a FDA decision has been pending for many months.  We don't know what is percolating in their useless minds.  They have had an extraordinary amount of time to decide yet  continue to dither.   They are overly cautious and will err on the side of NO rather than YES.

The track record of PLI doesn't help either.  They have never had a drug anywhere at anytime approved.  Their track record is near misses only.

My gut says it will be a go, but I don't think it will be this time around.  The FDA notoriously plays for time because the decisions they are to make are too complex for them.
Bullboard Posts